Navigation Links
Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018: Transparency Market Research

ALBANY, New York, November 28, 2012 /PRNewswire/ --

According to a new market report published by Transparency Market Research ( "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018," the global CINV market was worth USD 1.3 billion in 2011 and is expected to reach USD 2.1 billion in 2018, growing at a CAGR of 7.1% from 2013 to 2018. The North American CINV existing and pipeline drugs market is expected to reach USD 1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these regions.


Browse the full report at

Nausea and vomiting represent the most frequent side-effects experienced by chemotherapy patients, referred to as chemotherapy-induced nausea and vomiting (CINV), which is debilitating to cancer patients. Emetogenic refers to the likelihood of a chemotherapy drug affecting the patient in an adverse manner, leading to added illness or sickness. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 30-90% of the cases.

Current drug treatments available to prevent CINV have failed to completely overcome the symptoms of this disease. Moreover, most of the drugs are approved for acute-onset CINV whereas there is no drug approved yet for delayed-onset CINV for patients receiving HEC, which occurs more frequently (50-70% of patients) in the cancer population. The inefficiency to effectively predict CINV incidence and understand the complex physiology of CINV by healthcare providers coupled with the failure to adhere to recommended guidelines, have been prominent reasons for deficiency in CINV treatment.

Related & Recently Published Reports by Transparency Market Research

However, the current pipeline in the CINV market offers huge potential to overcome such unmet needs, with better and efficient drugs for both acute and the more prominent, delayed-onset CINV. Netu-palo FDC of Helsinn Healthcare, currently in phase III trials, which was in-licensed by the Helsinn group from Roche in the year 2005, helps in preventing CINV in acute as well as delayed-onset CINV patients. Due to its combination of a 5-HT3 antagonist and an NK-1 antagonist, the netu-palo FDC helps in overcoming unmet needs existing with current drug treatments available, which are mostly 5-HT3 antagonists. Moreover, other drugs in the pipeline, namely, APF530 and rolapitant offer physicians alternative treatment options for patients who show little relief from existing drugs in the market.

This research is specially designed to estimate and analyze the demand and performance of the CINV pipeline drugs in a global scenario. The research provides in-depth analysis of CINV pipeline drugs manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global CINV pipeline drugs market and provides detailed analysis, historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies, winning imperatives for them by segmenting the global CINV pipeline drugs market as below:

  • CINV - Pipeline Products

    APF530 (long-acting granisetron - 5-Ht3RA)

  • Efficacy Results of APF530 MEC Phase III Study
  • Efficacy Results of APF530 HEC Phase III Study

    Rolapitant (NK-1-RA)

    Chemical structure of rolapitant

    Netupitant-Palonosetron FDC

  • Introduction
  • Mechanism of action
  • Chemical structure of netupitant
  • Unmet Needs in the CINV Market
  • Clinical Trial Details for CINV pipeline drugs


  • Clinical Trial: ID- NCT00343460


  • Clinical Trial: ID - NCT01500226
  • Clinical Trial: ID - NCT01500213
  • Clinical Trial: ID - NCT01499849

    Netupitant-palonosetron FDC

  • Clinical Trial: ID - NCT01376297
  • Clinical Trial: ID - NCT01339260

In addition the report provides a cross-sectional analysis of all the above segments with respect to the following geographical markets:

North America


Browse all Pharmaceutical Market Research Reports:

Upcoming Reports in Pharmaceutical Industry

Neurostimulation Market

Sports Medicine Device Market

US Biopharmaceutical Market

Membrane Bioreactor (MBR) Market

Autologous Cell Therapy Market

Hormone Replacement Therapy Market

Freeze Drying Equipment Market

Antibiotic Market

Bio-Implants Market

Next Generation Sequencers Market

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
TMR on Web: Market Research Reports

SOURCE Transparency Market Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
2. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
3. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
4. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
5. First-of-its-kind self-assembled nanoparticle for targeted and triggered thermo-chemotherapy
6. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
7. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
8. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
9. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
10. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
11. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):